European CHMP recommends license extension of daratumumab (Darzalex) for multiple myeloma and AL amyloidosis

Proposed license extension for multiple myeloma is in combination with pomalidomide and dexamethasone for adults with disease progression after prior therapy; and for AL amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone in newly diagnosed adults.

European Medicines Agency